Trials / Terminated
TerminatedNCT00537602
Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | miglustat | |
| DRUG | placebo |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-02-01
- Completion
- 2008-03-01
- First posted
- 2007-10-01
- Last updated
- 2010-02-12
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00537602. Inclusion in this directory is not an endorsement.